195 related articles for article (PubMed ID: 27352631)
1. The role of pharmacogenetics in the treatment of osteosarcoma.
Vos HI; Coenen MJ; Guchelaar HJ; Te Loo DM
Drug Discov Today; 2016 Nov; 21(11):1775-1786. PubMed ID: 27352631
[TBL] [Abstract][Full Text] [Related]
2. Current understanding of pharmacogenetic implications of DNA damaging drugs used in osteosarcoma treatment.
Hattinger CM; Patrizio MP; Luppi S; Magagnoli F; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):299-311. PubMed ID: 30822170
[TBL] [Abstract][Full Text] [Related]
3. Can pharmacogenomics help to improve therapy in patients with high-grade osteosarcoma?
Kager L; Diakos C; Bielack S
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1025-8. PubMed ID: 25882838
[TBL] [Abstract][Full Text] [Related]
4. Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma.
Hattinger CM; Serra M
Expert Opin Drug Metab Toxicol; 2015; 11(9):1449-63. PubMed ID: 26095223
[TBL] [Abstract][Full Text] [Related]
5. The pharmacogenomics of osteosarcoma.
Serra M; Hattinger CM
Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.
Hattinger CM; Patrizio MP; Luppi S; Serra M
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629971
[TBL] [Abstract][Full Text] [Related]
7. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.
Hattinger CM; Tavanti E; Fanelli M; Vella S; Picci P; Serra M
Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):245-257. PubMed ID: 27758143
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.
Hattinger CM; Vella S; Tavanti E; Fanelli M; Picci P; Serra M
Pharmacogenomics; 2016 Dec; 17(18):2097-2114. PubMed ID: 27883291
[TBL] [Abstract][Full Text] [Related]
10. Osteosarcoma: the state of affairs dictates a change. What do we know?
Kleinerman ES; Mary V; John A
Adv Exp Med Biol; 2014; 804():vii-viii. PubMed ID: 25207354
[No Abstract] [Full Text] [Related]
11. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
Gougelet A; Pissaloux D; Besse A; Perez J; Duc A; Dutour A; Blay JY; Alberti L
Int J Cancer; 2011 Aug; 129(3):680-90. PubMed ID: 20949564
[TBL] [Abstract][Full Text] [Related]
12. Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study.
Windsor RE; Strauss SJ; Kallis C; Wood NE; Whelan JS
Cancer; 2012 Apr; 118(7):1856-67. PubMed ID: 21887680
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in osteosarcoma.
Botter SM; Neri D; Fuchs B
Curr Opin Pharmacol; 2014 Jun; 16():15-23. PubMed ID: 24632219
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of the Primary and Metastatic Osteosarcoma: Gene Expression Profile Associated with Outcome.
Trujillo-Paolillo A; Tesser-Gamba F; Seixas Alves MT; Filho RJG; Oliveira R; Petrilli AS; Toledo SRC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982681
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic changes in osteosarcoma.
Cui J; Wang W; Li Z; Zhang Z; Wu B; Zeng L
Bull Cancer; 2011 Jul; 98(7):E62-8. PubMed ID: 21708514
[TBL] [Abstract][Full Text] [Related]
17. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
18. Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy.
Sarver AE; Subramanian S
Epigenomics; 2016 Jul; 8(7):885-8. PubMed ID: 27366930
[No Abstract] [Full Text] [Related]
19. HER-2 involvement in osteosarcoma.
Gill J; Geller D; Gorlick R
Adv Exp Med Biol; 2014; 804():161-77. PubMed ID: 24924174
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for Bone Sarcoma in Adults.
Wagner MJ; Livingston JA; Patel SR; Benjamin RS
J Oncol Pract; 2016 Mar; 12(3):208-16. PubMed ID: 26962160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
